Clinical trials: Immunization
Respiratory Syncytial Virus Immunization
Repeated Cross Sectional Surveillance Study To Determine the Respiratory Syncytial Virus (RSV) Immunization Rates in German Infants
In June 2024, the German Standing Committee on Vaccination (STIKO) recommended the universal immunization of infants with nirsevimab during their first RSV season.
- Trial name
- Vakzimeter RSV (NCT06824207)
- Where
- Germany
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
RSV Immunization
Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination
RSV (which stands for Respiratory Syncytial Virus) is an infection that causes cold-like symptoms and is most common during winter months.
- Trial name
- PIPELINE-RSV-F (NCT07232706)
- Testing
- Nirsevimab, Abrysvo
- Where
- France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Annecy Genevois
Group B Streptococcus, Invasive Bacterial Diseases (IBD)
Preparing for Maternal GBS Vaccine Trials in Africa
Infections are one of the key causes of newborn deaths. Among them, Group B Streptococcus (GBS) is the leading cause of sepsis and bacterial meningitis in the first 90 days of life.
- Conditions
- Group B Streptococcus, Invasive Bacterial Diseases (IBD), Maternal Immunization
- Trial name
- PROTECT (NCT06833957)
- Where
- 10 sites in Kenya, Malawi and 2 more
- Volunteers
- 18,100 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
COVID-19 Immunization, Influenza Immunization
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
Study VBT00001 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States.
- Trial name
- NCT06695117
- Testing
- IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1)
- Where
- 12 sites in United States
- Volunteers
- 980 people, healthy volunteers welcome
- Sponsor
- Sanofi
COVID-19 Immunization, Influenza Immunization
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older
Study VBT00002 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States.
- Trial name
- NCT06695130
- Testing
- RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1)
- Where
- 12 sites in United States
- Volunteers
- 980 people, healthy volunteers welcome
- Sponsor
- Sanofi
Vaccine Hesitancy, Health Education
Effect of Primary Care Education on Parents' Health-Related Perceptions and Attitudes
This study aims to evaluate the effect of a structured education program delivered in primary health care settings on parents of children aged 0-2 years.
- Conditions
- Vaccine Hesitancy, Health Education, Digital Health Literacy, Eco-anxiety
- Trial name
- NCT07381088
- Testing
- Structured Education Program
- Where
- Turkey (Türkiye)
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Yuzuncu Yil University
Respiratory Syncytial Virus Immunization
Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different liponanaoparticle (LNP) formulations of modified ribonucleic acid (mRNA) vaccines using the RSV pre-F antigen in healthy participants 18 to 49…
- Trial name
- NCT07071558
- Testing
- RSV vaccine formulation 1 dose, RSV vaccine formulation 2 dose, RSV vaccine formulation 3 dose
- Where
- 6 sites in Australia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza Immunization
Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older
The purpose of this study is to evaluate a pandemic flu H5 strain messenger ribonucleic acid (mRNA) vaccine at 3 dose levels (low, medium, and high) in comparison with placebo in 276 healthy adult participants to select the…
- Trial name
- NCT06727058
- Testing
- Pandemic flu H5 mRNA vaccine
- Where
- 14 sites in United States
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumococcal Immunization
Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate vaccine) is safe and can help the body to develop germ-fighting agents called…
- Trial name
- NCT06736041
- Testing
- PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine
- Where
- 112 sites in United States, Australia and 4 more
- Volunteers
- 1,714 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Immunization, Efficacy
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
The investigators are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it…
- Conditions
- Immunization, Efficacy, Human Papilloma Virus
- Trial name
- NCT03943875
- Testing
- 9-valent HPV vaccine, 2 dose efficacy, 9-valent HPV vaccine, 3 doses standard timing
- Where
- United States
- Volunteers
- 767 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Pneumococcal Immunization
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
This study is a Phase 3, randomized, modified double-blind study which aims to document the safety profile of the PCV21 vaccine (investigational pneumococcal vaccine) compared to a licensed 20-valent pneumococcal conjugate…
- Trial name
- NCT06824194
- Testing
- PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine
- Where
- 132 sites in United States, Honduras and 4 more
- Volunteers
- 2,360 people, healthy volunteers welcome
- Sponsor
- Sanofi
Chlamydia Trachomatis Immunization
Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years
The purpose of this study is to evaluate the safety, efficacy, and immunogenicity of different dose levels (low, medium, and high) of Chlamydia messenger ribonucleic acid (mRNA) Vaccine candidate in adult participants aged 18 to…
- Trial name
- NCT06891417
- Testing
- Chlamydia mRNA Vaccine
- Where
- 7 sites in Australia
- Volunteers
- 1,560 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza Immunization, Health Volunteers
A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire
This study aims to assess patient-reported experiences following trivalent recombinant influenza vaccine (RIV3) vaccination using the Vaccinees' Perception of Injection (VAPI) questionnaire, identify factors related to vaccine…
- Trial name
- NCT06765187
- Testing
- Trivalent Recombinant Influenza Vaccine
- Where
- United States
- Volunteers
- 1,007 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy, Immunization; Infection
BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers
As previously shown, individuals who experienced COVID-19 have developed some protective immunity to reinfection. The magnitude and duration of protection from reinfection conferred by the infection may be weaker after an…
- Trial name
- CoviCompareP (NCT04824638)
- Testing
- 3 doses of BNT162b2 vaccine, 2 dose of BNT162b2 vaccine
- Where
- 11 sites in France
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
RSV Immunization
Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India
The purpose of this study is to describe the safety and efficacy outcomes associated with the use of nirsevimab, administered as per routine clinical practice, in neonates and infants aged 0 to 12 months born during or entering…
- Trial name
- NCT07109297
- Testing
- Nirsevimab
- Where
- 7 sites in India
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza, Immunization
Influenza Immunization in Adults Over Age 75
The immune system is the part of the body that protects against infection. The immune system often doesn't work as effectively as people get older.
- Conditions
- Influenza, Immunization, Older Adults, Over Age 75
- Trial name
- NCT02200276
- Testing
- Influenza
- Where
- United States
- Volunteers
- 1,025 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Pneumococcal Immunization, Safety
A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market
The purpose of this study is to understand the safety of Prevenar 20 (Pneumococcal 20-valent conjugate vaccine) once it is out in the Korean market.
- Trial name
- NCT06760208
- Testing
- Pneumococcal 20-valent conjugate vaccine
- Where
- South Korea
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza Immunization
Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants
Real-time monitoring of vaccination rates for Germany is unavailable, and up-to-date data publication is delayed, which makes it challenging to develop effective public health strategies to increase vaccination coverage.
- Trial name
- Vakzimeter FLU (NCT06800885)
- Where
- Germany
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumococcal Immunization, Healthy Volunteers
Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate vaccine) is safe and can help the body to develop germ-fighting agents called…
- Trial name
- NCT06975878
- Testing
- PCV21 vaccine, Vaxneuvance vaccine, Hexyon vaccine
- Where
- 49 sites in Belgium, Czechia and 6 more
- Volunteers
- 1,092 people, healthy volunteers welcome
- Sponsor
- Sanofi
Pneumococcal Immunization
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether the investigational pneumococcal conjugate vaccine PCV21 is safe and can help the body to develop germ-fighting agents called…
- Trial name
- NCT06824181
- Testing
- PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine
- Where
- 27 sites in United States, Chile and 2 more
- Volunteers
- 580 people, healthy volunteers welcome
- Sponsor
- Sanofi